EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacological validation of dihydrofolate reductase as a drug target in Mycobacterium abscessus

Wassihun Wedajo Aragaw, Dereje A Negatu, Christopher J Bungard, Véronique A Dartois iD, Abdellatif El Marrouni, Elliott B Nickbarg, David B Olsen, Ralf Warrass, Thomas Dick iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00717-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Wassihun Wedajo Aragaw und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Discovery and Innovation, Hackensack Meridian Health , Nutley, New Jersey, USA. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Folic Acid Antagonists, Mycobacterium tuberculosis, Mycobacterium Infections, Nontuberculous. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Mycobacterium abscessus drug development pipeline is poorly populated, with particularly few validated target-lead couples to initiate de novo drug discovery. Trimethoprim, an inhibitor of dihydrofolate reductase (DHFR) used for the treatment of a range of bacterial infections, is not active against M. abscessus . Thus, evidence that M. abscessus DHFR is vulnerable to pharmacological intervention with a small molecule inhibitor is lacking. Here, we show that the pyrrolo-quinazoline PQD-1, previously identified as a DHFR inhibitor active against Mycobacterium tuberculosis , exerts whole cell activity against M. abscessus . Enzyme inhibition studies showed that PQD-1, in contrast to trimethoprim, is a potent inhibitor of M. abscessus DHFR and over-expression of DHFR causes resistance to PQD-1, providing biochemical and genetic evidence that DHFR is a vulnerable target and mediates PQD-1’s growth inhibitory activity in M. abscessus . As observed in M. tuberculosis , PQD-1 resistant mutations mapped to the folate pathway enzyme thymidylate synthase (TYMS) ThyA. Like trimethoprim in other bacteria, PQD-1 synergizes with the dihydropteroate synthase (DHPS) inhibitor sulfamethoxazole (SMX), offering an opportunity to exploit the successful dual inhibition of the folate pathway and develop similarly potent combinations against M. abscessus . PQD-1 is active against subspecies of M. abscessus and a panel of clinical isolates, providing epidemiological validation of the target-lead couple. Leveraging a series of PQD-1 analogs, we have demonstrated a dynamic structure-activity relationship (SAR). Collectively, the results identify M. abscessus DHFR as an attractive target and PQD-1 as a chemical starting point for the discovery of novel drugs and drug combinations that target the folate pathway in M. abscessus .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium abscessusFolic Acid AntagonistsMycobacterium tuberculosisMycobacterium Infections, NontuberculousHumansTetrahydrofolate DehydrogenaseTrimethoprimEnzyme InhibitorsFolic Acid

Stichwörter der Autor:innen

DHFRDHPSNTMThyAfolate pathwaynon-tuberculous mycobacteriasynergy

Substanzen

Tetrahydrofolate DehydrogenaseFolic Acid AntagonistsTrimethoprimEnzyme InhibitorsFolic Acid

Autor:innen und Institutionen

  • Center for Discovery and Innovation, Hackensack Meridian Health , Nutley, New Jersey, USA.
  • Merck & Co., Inc. , West Point, Pennsylvania, USA.
  • Department of Medical Sciences, Hackensack Meridian School of Medicine , Nutley, New Jersey, USA.
  • Merck & Co., Inc. , Boston, Massachusetts, USA.
  • MSD Animal Health Innovation GmbH, Zur Propstei , Schwabenheim, Germany.
  • Department of Microbiology and Immunology, Georgetown University , Washington, USA.

ORCID-Profile: Véronique A Dartois, Thomas Dick

Förderung

  • NIAID NIH HHS
  • HHS | National Institutes of Health

Zitieren

APA

Aragaw, W. W., Negatu, D. A., Bungard, C. J., Dartois, V. A., Marrouni, A. E., Nickbarg, E. B., Olsen, D. B., Warrass, R., & Dick, T. (2024). Pharmacological validation of dihydrofolate reductase as a drug target in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00717-23

Vancouver

Aragaw WW, Negatu DA, Bungard CJ, Dartois VA, Marrouni AE, Nickbarg EB, et al. Pharmacological validation of dihydrofolate reductase as a drug target in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00717-23

BibTeX
@article{Aragaw2024,
  author = {Aragaw, Wassihun Wedajo and Negatu, Dereje A and Bungard, Christopher J and Dartois, Véronique A and Marrouni, Abdellatif El and Nickbarg, Elliott B and Olsen, David B and Warrass, Ralf and Dick, Thomas},
  title = {Pharmacological validation of dihydrofolate reductase as a drug target in Mycobacterium abscessus},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00717-23}
}
Kostenlos starten →